Tim Smith

Research indicates that a potential reduction in healthcare costs could result from utilization of biosimilars for adalimumab and etanercept in dermatology.

In another interview segment, Castells went further into depth regarding the PIONEER trial results and regarding avapritinib’s effect on mastocytosis.

New data from AAAAI was described by Castells, who explained some of the background of the recent PIONEER trial on avapritinib for mastocytosis patients.

Novan announced on Tuesday that the FDA accepted the New Drug Application (NDA) for Berdazimer Gel, a topical antiviral molluscum contagiosum treatment, for review.

In a recent letter to the editor, a newly-developed tool to assess one’s satisfaction with life when dealing with food allergy was introduced.

A recent study reviewed several educational interventions designed to promote food allergy literacy and knowledge for both parents and children.

New data from a study on adult vitiligo patients indicates that both autoimmune/autoinflammatory and non-autoimmune comorbidities have higher occurrence rates for vitiligo patients.

New findings have indicated that alopecia areata, alopecia totalis, and alopecia universalis, may disproportionately affect Asian Americans and other people of color.

In recent data presented at the AAAAI annual meeting, dupilumab was found to have outperformed both mepolizumab and omalizumab in FEV1 improvement for asthma patients.

Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.

Data presented at the AAAAI annual conference showed that delayed cutaneous reactions were more reported following Moderna COVID-19 vaccination than other vaccines.

New data presented at the AAAAI annual meeting showed that a significant number of patients recommended to be evaluated for drug allergy never completed their diagnostic tests.

Data presented at the AAAAI annual meeting showed that machine learning models had a high accuracy rate in penicillin allergy prediction, though researchers concluded that more data is needed before adoption.

Recent data, presented at the AAAAI annual meeting, showed that oral sesame desensitization through crushed seeds and tahini was efficacious and safe for pediatric patients.

In this interview segment at AAAAI, Altman went into a discussion on challenges to systems biology approaches for allergic disease.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

An interview featured Bird discussing data from his AAAAI annual meeting presentation on a new oral immunotherapy product for those with peanut allergies.

New data presented at the 2023 AAAAI Annual Meeting indicated that infants with anaphylaxis had different symptoms from those who were older, with greater involvement in other areas.

In another recent HCPLive interview at AAAAI, Altman described examples of systems biology approaches to allergic disease and the importance of cross-disciplinary collaboration.

Altman spoke in a recent interview about the main takeaways from his AAAAI presentation, during which he discussed systems biology research into allergic diseases.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

In an interview regarding his AAAAI poster session, Dellon described a sub-analysis of new phase 3 trial data on dupilumab for eosinophilic esophagitis patients.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’